Articles tagged with: HPV
Bristol-Myers Squibb, Gilead To Create New, Boosted Reyataz Pill – Bristol-Myers Squibb and Gilead Sciences announced an agreement last week to create a new, all-in-one boosted Reyataz (atazanavir) pill. The pill will contain Gilead Science’s investigational booster cobicistat. The combination of Reyataz and cobicistat is being evaluated in Phase 2 and Phase 3 clinical trials. Under the agreement, Bristol-Myers Squibb will be responsible for marketing the new drug. Boosting agents are used to increase the concentration of another drug in the bloodstream and allow patients to take drugs less often without losing efficacy. Currently the only antiretroviral booster approved by the U.S. Food and Drug Administration is Norvir (ritonavir). For more information, please see the press release from Bristol-Myers Squibb.
HIV Drug Patch Shows Efficacy In Preclinical Tests – Results from preclinical studies indicate that a new investigational skin patch is effective at delivering antiretroviral drugs. The patch contained a non-nucleoside reverse transcriptase inhibitor that is in early stages of development. Results showed that the patch successfully released 96 percent of the drug over seven days. The study authors stated that the skin patch could be an easier alternative to pills for people with HIV who have problems with adherence. The patch will be tested further in a Phase 1 clinical trial. For more information, please see the study abstract (pdf) and press release at the American Association of Pharmaceuticals Scientists website or the U.S. News and World Report article.
HPV Vaccine May Prevent Anal Cancer In Men Who Have Sex With Men – Results from a large international study indicate that the human papillomavirus (HPV) vaccine Gardasil effectively prevents anal pre-cancerous lesions in men who have sex with men. The study included 602 men aged 16 to 26 years old. Results showed that the vaccine reduced the rate of pre-cancerous lesions by 78 percent. To be effective the vaccine must be given before men acquire HPV, which causes most cases of anal cancer. Researchers have estimated that people with HIV are 30 to 50 times more likely to get anal cancer than people without HIV, and men who have sex with men are around 60 times more likely to get anal cancer. For more information, please see the study in the New England Journal of Medicine (abstract) or the article from Agence France-Presse.
United States Conference On AIDS Begins November 10 – The 2011 United States Conference on AIDS (USCA) will be held November 10 to 13 in Chicago. Topics covered during the conference include HIV prevention, treatment, and research as well as housing and public policy. Among the speakers are David Furnish, Chairman of the Elton John AIDS Foundation; Mondo Guerra, the HIV-positive former contestant from the television show Project Runway; and Senator Jack Jackson (AZ), a member of the President’s Advisory Council on HIV/AIDS. Over 3,000 people are expected to attend this year’s conference. For more information or to register for the conference, please see the USCA 2011 website.
Illinois Tightens Income Requirements For Its AIDS Drug Assistance Program – The Illinois Department of Public Health has announced that as of July 1, new applicants to the state’s AIDS Drug Assistance Program (ADAP) will only be accepted if their income falls at or below 300 percent of the federal poverty line, less than or equal to $32,670 for a single individual. Currently, access to the ADAP in Illinois is restricted to those who have an income at or below 500 percent of the federal poverty level ($54,450 for a single individual). The Illinois ADAP is funded by both the federal and state governments and provides assistance to approximately 4,200 people living with HIV and AIDS. The recent economic downturn has led to more people requiring aid, while funds for the ADAP have been decreasing. For more information, please see the Windy City Times or the announcement from the Illinois Department of Public Health.
New York State Department Of Health Releases Guidelines On Prevention Of Secondary HIV Transmission – The New York State Department of Health AIDS Institute has released guidelines for the prevention of secondary HIV transmission, titled “Prevention with Positives: Integrating HIV Prevention into HIV Primary Care.” The guidelines recommend that people with HIV undergo sexual risk assessments every three to four months. They also suggest that health care providers discuss risk reduction strategies with their patients on an individualized basis. People with HIV should be screened annually for sexually transmitted infections and educated about HIV viral load (amount of HIV in the blood), transmission risk, and safe sex practices. Additionally, health care providers should review substance abuse history with each patient and discuss avoiding syringe or needle sharing with all injection drug users. For more information, please see the New York AIDS Institute website.
FDA Approves New Human Papillomavirus Test For Cervical Cancer Screening In Women – Roche announced last week that the U.S. Food and Drug Administration (FDA) has approved its cobas Human Papillomavirus (HPV) test, which screens women for the two HPV strains most commonly associated with cervical cancer. The approval was based on a clinical trial in 47,000 women that showed that 10 percent of women who tested positive for HPV strains 16 or 18 had pre-cervical cancer, even though they had normal Pap smear results. Most women with HIV (75 to 80 percent) also have HPV, and women with HIV are at higher risk of cervical cancer (see related AIDS Beacon news); studies estimate that 20 to 60 percent of women with HIV have signs of pre-cervical cancer. The new test is designed for use in addition to a routine Pap smear. For more information, please see the Roche press release.
Results of a recent study suggest that women who adhere to their antiretroviral regimens or have effective antiretroviral treatment regimens have lower rates of human papillomavirus infection and faster clearance of pre-cancerous cervical lesions.
The results may explain why age-specific cervical cancer rates among HIV-positive women have not increased with the rise of highly active antiretroviral therapy (HAART) even though women with HIV are living longer. However, the researchers stated that they still expect the overall rates of cervical cancer in the HIV-positive population to increase since older women have …
A U.S. Food and Drug Administration advisory committee has recommended the approval of Merck’s Gardasil vaccine for the prevention of human papillomavirus-related anal cancer and precancerous anal lesions in both men and women 9 through 26 years of age.
Although the Food and Drug Administration (FDA) does not have to follow the recommendations of the advisory committee, it usually does.
Gardasil (Human Papillomavirus Quadrivalent (types 6, 11, 16, and 18) Vaccine, Recombinant) is a three-dose vaccine meant to protect against diseases caused by the human papillomavirus (HPV). HPV causes genital …